The assessment of the Long Term Hematologic Effects in Differentiated Thyroid Cancer Patients Treated with Radioactive Iodine

xlomafota13 shared this article with you from Inoreader The assessment of the Long Term Hematologic Effects in Differentiated Thyroid Cancer Patients Treated with Radioactive Iodine Via radioactive iodine Turk J Haematol. 2021 Mar 22. doi: 10.4274/tjh.galenos.2021.2021.0092. Online ahead of print. ABSTRACT OBJECTIVE: Radioactive iodine (RAI) therapy may cause hematological abnormalities. The aim of the study is to evaluate long-term hematological changes in differentiated thyroid cancer (DTC) patients after RAI therapy. MATERIALS AND METHODS: One thousand three hundred eighty nine patients with DTC who were treated with RAI were retrospectively evaluated. Complete blood cell c ounts before the RAI therapy and last follow up and hematologic malignancy development were obtained from the electronic records. RESULTS AND CONCLUSION: In the long term analysis, thrombocytopenia and lymphopenia were observed significantly over 60 years of age. We suggested that, these cytopenias should be surveyed more carefully in this group of age. Thrombocytopenia was observed more frequently in men. Leukopenia, thrombocytopenia and lymphopenia were observed significantly with >175 mCI doses. Thrombocytopenia and lymphopenia were observed significantly with multiple dose administration. The higher frequency of anemia, thrombocytopenia, leukopenia, neutropenia, and lymphopenia were found in patients with advanced stage disease. However patients with advanced stage disease had higher doses and multiple doses than patients with early stage disease. The rate of hematological malignancy was found to be higher than the general population. PMID:33749216 | DOI:10.4274/tjh.galenos.2021.2021.0092 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.